Search Results Heading

Mohammed Bin Rashid Library /
Catalogue /
Catalogue Search

Explore the vast range of titles available.

MBRLSearchResults

mbrl.module.common.modules.added.book.to.shelf
Title added to your shelf!
View what I already have on My Shelf.
Thanks
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Done
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
{{itemTitle}}
by {{itemAuthor}} In {{itemCategory}}, {{itemType}}
Confirm
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Done
    Done
    Filters
    Reset
  • Discipline
      Done
      Discipline
      Clear All
      Discipline
  • Is Peer Reviewed
      Done
      Is Peer Reviewed
      Clear All
      Is Peer Reviewed
  • Item Type
      Done
      Item Type
      Clear All
      Item Type
  • Subject
      Done
      Subject
      Clear All
      Subject
      • Add
      Clear Filters
  • Year
      Done
      Year
      Clear All
      From:
      -
      To:
  • More Filters
2 result(s) for "Modelska, Katharina"
Sort by:
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
by Hussain, Maha , Madziarska, Katarzyna , Fizazi, Karim in Adenocarcinoma - drug therapy , Adenocarcinoma - mortality , Aged
2020
Among men with high-risk, nonmetastatic, castration-resistant prostate cancer, the addition of enzalutamide to androgen-deprivation therapy improved overall survival by nearly a year as compared with ADT alone: median survival was 67 months with enzalutamide plus ADT and 56 months with ADT alone.
Journal Article
Share this book
Add to My Shelf
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
by Phung, De , Hussain, Maha , Sternberg, Cora N in Adenocarcinoma - blood , Adenocarcinoma - drug therapy , Adenocarcinoma - mortality
2018
In a trial, the median metastasis-free survival among men with nonmetastatic, castration-resistant prostate cancer and a short PSA doubling time was 36.6 months with enzalutamide and 14.7 months with placebo. Falls and heart problems were more common with enzalutamide.
Journal Article
Share this book
Add to My Shelf